NCT00220389View on ClinicalTrials.gov

Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

June 30, 2003

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions

Overactive Bladder

Interventions

DRUG

SPM 907

Trial Locations (1)

Unknown

Schwarz, RTP

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT00220389 - Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase | Biotech Hunter | Biotech Hunter